Update, August 23, 2026: a week on, this is still where things stand. No order has published — we re-checked the Federal Register the morning this note went up, and the newest 7-OH filings remain the July 6 notices. Our latest piece covers what the continued silence does and doesn't mean. The original article follows.
Not today. As of August 16, 2026, 7-OH is still not a federally controlled substance — we checked the Federal Register before publishing this. But the DEA has now cleared every procedural step it needs, and the order can land any day, without further notice.
Here is where things actually stand. On July 6, 2026, the DEA published its notice of intent to place 7-hydroxymitragynine above a specified threshold into Schedule I on a temporary basis, along with three related compounds: mitragynine pseudoindoxyl, MGM-15, and MGM-16. Federal law requires the agency to wait at least 30 days after that notice before issuing the actual order. That window closed on August 5.
The threshold is worth understanding, because it decides what is covered. The order targets material containing more than 0.05% 7-OH by weight or volume, or more than one milligram per article. Plain kratom leaf that falls below that line is not included. The concentrated tablets, shots, and gummies sold behind gas-station counters are precisely what is.
This is the detail that gets lost in most coverage: a temporary scheduling order takes effect the day it publishes in the Federal Register. Not thirty days later, not at the start of the next quarter. There is no sell-through period and no grace window. Shelves that are full on a Tuesday can be empty on a Wednesday.
If you are using 7-OH every day, that is not a policy story. That is your supply potentially disappearing overnight — and 7-OH withdrawal is opioid withdrawal. Same sickness, same timeline, same reason people go back to using just to stop feeling it. A ban can be good public-health policy and a personal emergency at the same time, and both of those things are true here.
So the useful move is to talk to a clinician before the shelves clear, not after. Buprenorphine, the same medication used for opioid use disorder, is used for 7-OH dependence. When you go, be specific: which brand, how many milligrams, how many times a day, how long you have been at it. People almost always undercount, and no one can plan around a number that isn't real.
For Camden County readers, this matters more than it does in states that already acted. New Jersey has no 7-OH ban on the books — the Schedule I bill that cleared the Senate health committee in March has not become law. If the federal order publishes first, it would be the first real prohibition to reach South Jersey shelves, and it would arrive without the months of notice a state bill would have given.
One safety note we will repeat as often as it takes: do not stop abruptly on your own to get ahead of this. Talk to a doctor, an urgent care, or a treatment program first. If you are in crisis, call or text 988. For treatment referrals any time, day or night, SAMHSA is at 1-800-662-4357. This is education, not medical advice — your situation belongs in front of someone licensed to look at it.